Literature DB >> 15454671

Evaluation of the interactions of common genetic mutations in stroke.

Zoltán Szolnoki1.   

Abstract

Stroke is a common entity. It is the third leading cause of death and the leading cause of adult disability in the developed world. More than 110 heritable disorders, more than 175 genetic loci, and more than 2050 unique mutations predisposing to stroke are known. Although ischemic stroke can result from merely one gene defect (and a number of clearly defined mendelian hereditary disorders do lead to stroke), the interaction of unfavorable genetic factors such as the Leiden V, methylenetetrahydrofolate reductase (MTHFR) 677TT, apolipoprotein E (ApoE) 4, and angiotensin-converting enzyme (ACE) D/D genotypes, which alone are not major risk factors, can in specific patterns exert a synergistic effect on certain clinical risk factors. This chapter discusses how to evaluate these interactions and the interpretation of findings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15454671     DOI: 10.1385/1-59259-836-6:241

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  3 in total

1.  Interaction of angiotensin-converting enzyme and apolipoprotein E gene polymorphisms in ischemic stroke involving large-vessel disease.

Authors:  Sarra Saidi; Walid Zammiti; Lamia B Slamia; Sofyan B Ammou; Wassim Y Almawi; Touhami Mahjoub
Journal:  J Thromb Thrombolysis       Date:  2007-11-21       Impact factor: 2.300

2.  ACE-II genotype and I allele predicts ischemic stroke among males in south India.

Authors:  Murali Vijayan; Rathika Chinniah; Padma Malini Ravi; Arun Kumar Mosses Joseph; Neethi Arasu Vellaiappan; Jeyaram Illiayaraja Krishnan; Balakrishnan Karuppiah
Journal:  Meta Gene       Date:  2014-09-28

3.  Synergistic effects of ACE (I/D) and Apo E (Hha I) gene polymorphisms on obesity, fat mass, and blood glucose level among the adult Asian Indians: A population-based study from Calcutta, India.

Authors:  Mithun Das; Susil Pal; Arnab Ghosh
Journal:  Indian J Endocrinol Metab       Date:  2013-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.